A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer
Latest Information Update: 10 Apr 2023
Price :
$35 *
At a glance
- Drugs BS-006 (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- 05 Apr 2023 Planned primary completion date changed from 1 Jul 2023 to 31 Dec 2023.
- 05 Apr 2023 Status changed from not yet recruiting to recruiting.
- 03 Jun 2022 New trial record